MicroRNAs As Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jul 27

PMID 35886942

Authors

Maria Konoshenko

Yuriy Lansukhay

Sergey Krasilnikov

Pavel Laktionov

Affiliations

Soon will be listed here.

Abstract

Background: Platinum-based chemotherapy, cisplatin (DDP) specifically, is the main strategy for treating lung cancer (LC). However, currently, there is a lack of predictive drug-resistance markers, and there is increased interest in the development of a reliable and sensitive panels of markers for DDP chemotherapy-effectiveness prediction. MicroRNAs represent a perspective pool of markers for chemotherapy effectiveness.

Objectives: Data on miRNAs associated with LC DDP chemotherapy response are summarized and analyzed.

Materials And Methods: A comprehensive review of the data in the literature and an analysis of bioinformatics resources were performed. The gene targets of miRNAs, as well as their reciprocal relationships with miRNAs, were studied using several databases.

Results And Discussion: The complex analysis of bioinformatics resources and the literature indicated that the expressions of 12 miRNAs have a high predictive potential for LC DDP chemotherapy responses. The obtained information was discussed from the point of view of the main mechanisms of LC chemoresistance.

Conclusions: An overview of the published data and bioinformatics resources, with respect to the predictive microRNA markers of chemotherapy response, is presented in this review. The selected microRNAs and gene panel have a high potential for predicting LC DDP sensitiveness or DDP resistance as well as for the development of a DDP co-therapy.

Citing Articles

USP5-dependent HDAC1 promotes cisplatin resistance and the malignant progression of non-small cell lung cancer by regulating RILP acetylation levels.

Lu R, Jin Y, Zheng M Thorac Cancer. 2024; 16(1):e15478.

PMID: 39582290 PMC: 11729750. DOI: 10.1111/1759-7714.15478.

DNA hypomethylation of INHBA promotes tumor progression and predicts prognosis and immune status of gastric cancer.

Li X, Jiang H, Fu Y, Hu Q, Cai X, Xu G Hereditas. 2024; 161(1):45.

PMID: 39543755 PMC: 11562481. DOI: 10.1186/s41065-024-00347-7.

miR-149-3p targeting regulates the sensitivity to cisplatin to inhibit the progression of lung cancer.

Qin B, Tang D, Zhang M Biomol Biomed. 2024; 25(1):165-176.

PMID: 39388706 PMC: 11647265. DOI: 10.17305/bb.2024.11163.

Integrated analysis reveals critical cisplatin-resistance regulators E2F7 contributed to tumor progression and metastasis in lung adenocarcinoma.

Mao X, Xu S, Wang H, Xiao P, Li S, Wu J Cancer Cell Int. 2024; 24(1):173.

PMID: 38760774 PMC: 11102206. DOI: 10.1186/s12935-024-03366-6.

TP53 mitigates cisplatin resistance in non-small cell lung cancer by mediating the effects of resistant cell-derived exosome mir-424-5p.

Deng Y, Ding H, Zhang Y, Feng X, Ye Q, Tian R Heliyon. 2024; 10(5):e26853.

PMID: 38439876 PMC: 10909722. DOI: 10.1016/j.heliyon.2024.e26853.

References

Fu J, Cai H, Wu Y, Fang S, Wang D . Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Gene. 2020; 755:144886. DOI: 10.1016/j.gene.2020.144886. View

Liu C, Hu W, Li L, Wang Y, Zhou Q, Zhang F . Roles of miR-200 family members in lung cancer: more than tumor suppressors. Future Oncol. 2018; 14(27):2875-2886. DOI: 10.2217/fon-2018-0155. View

Li Q, Xie Y, Wu Y, Li L, Liu Y, Miao X . Sulforaphane inhibits cancer stem-like cell properties and cisplatin resistance through miR-214-mediated downregulation of c-MYC in non-small cell lung cancer. Oncotarget. 2017; 8(7):12067-12080. PMC: 5355326. DOI: 10.18632/oncotarget.14512. View

Gu Y, Zhang Z, Yin J, Ye J, Song Y, Liu H . Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1). J Exp Clin Cancer Res. 2017; 36(1):114. PMC: 5580233. DOI: 10.1186/s13046-017-0582-5. View

Zhang F, Li Y, Wu H, Qi K, You J, Li X . [MiR-192 confers cisplatin resistance by targeting Bim in lung cancer]. Zhongguo Fei Ai Za Zhi. 2014; 17(5):384-90. PMC: 6000442. DOI: 10.3779/j.issn.1009-3419.2014.05.04. View

Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou X . miR-135a/b modulate cisplatin resistance of human lung cancer cell line by targeting MCL1. Pathol Oncol Res. 2013; 19(4):677-83. DOI: 10.1007/s12253-013-9630-4. View

Yuwen D, Sheng B, Liu J, Wenyu W, Shu Y . MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2017; 21(11):2650-2658. View

Chao W, Deng J, Li P, Liang Y, Huang G . 3,4-Dihydroxybenzalactone Suppresses Human Non-Small Cell Lung Carcinoma Cells Metastasis via Suppression of Epithelial to Mesenchymal Transition, ROS-Mediated PI3K/AKT/MAPK/MMP and NFκB Signaling Pathways. Molecules. 2017; 22(4). PMC: 6154291. DOI: 10.3390/molecules22040537. View

Inoue Y, Matsumoto H, Yamada S, Kawai K, Suemizu H, Gika M . Association of ATP7A expression and in vitro sensitivity to cisplatin in non-small cell lung cancer. Oncol Lett. 2012; 1(5):837-840. PMC: 3436384. DOI: 10.3892/ol_00000147. View

10.

Fan T, Wang W, Zhang B, Xu Y, Chen L, Pan S . Regulatory mechanisms of microRNAs in lung cancer stem cells. Springerplus. 2016; 5(1):1762. PMC: 5056920. DOI: 10.1186/s40064-016-3425-5. View

11.

Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti G, Papotti M . Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 2010; 8(9):1207-16. DOI: 10.1158/1541-7786.MCR-10-0052. View

12.

Fang C, Chen Y, Wu N, Yin J, Li X, Huang H . MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Sci Rep. 2017; 7:40384. PMC: 5225486. DOI: 10.1038/srep40384. View

13.

Xu S, Li J, Chen L, Guo L, Ye M, Wu Y . Plasma miR-32 levels in non-small cell lung cancer patients receiving platinum-based chemotherapy can predict the effectiveness and prognosis of chemotherapy. Medicine (Baltimore). 2019; 98(42):e17335. PMC: 6824696. DOI: 10.1097/MD.0000000000017335. View

14.

Ji K, Cui F, Qu D, Sun R, Sun P, Chen F . MiR-378 promotes the cell proliferation of non-small cell lung cancer by inhibiting FOXG1. Eur Rev Med Pharmacol Sci. 2018; 22(4):1011-1019. DOI: 10.26355/eurrev_201802_14383. View

15.

Yang W, Xiao W, Cai Z, Jin S, Li T . miR-1269b Drives Cisplatin Resistance of Human Non-Small Cell Lung Cancer via Modulating the PTEN/PI3K/AKT Signaling Pathway. Onco Targets Ther. 2020; 13:109-118. PMC: 6954839. DOI: 10.2147/OTT.S225010. View

16.

Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J . miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol. 2011; 69(3):723-31. DOI: 10.1007/s00280-011-1752-3. View

17.

Weber J, Baxter D, Zhang S, Huang D, Huang K, Lee M . The microRNA spectrum in 12 body fluids. Clin Chem. 2010; 56(11):1733-41. PMC: 4846276. DOI: 10.1373/clinchem.2010.147405. View

18.

Wang H, Zhu L, Yang Y, Wang Z, Wang R . MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer. 2014; 111(2):339-54. PMC: 4102932. DOI: 10.1038/bjc.2014.157. View

19.

Wu H, Mu X, Liu L, Wu H, Hu X, Chen L . Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death Dis. 2020; 11(9):801. PMC: 7519084. DOI: 10.1038/s41419-020-02962-4. View

20.

Hao G, Hao H, Ding Y, Wen H, Li X, Wang Q . Suppression of EIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells. FEBS Lett. 2017; 591(4):636-645. DOI: 10.1002/1873-3468.12566. View